Arecor Therapeutics plc

AREC

GB00BMWLM973

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:30 2025-01-13 am EST			5-day change	1st Jan Change
58.50 ^GBX	0.00%		-20.95%	-20.41%

Jan. 10	Arecor Therapeutics shares tumble as plans Tetris wind-down	AN
Jan. 10	Arecor Therapeutics to Shutter Tetris Pharma Unit; Ends License Deal with Xeris	MT

Arecor Therapeutics Names Interim CFO

November 18, 2024 at 04:33 am EST

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Arecor Therapeutics plc

Arecor Therapeutics shares tumble as plans Tetris wind-down	Jan. 10	AN
Arecor Therapeutics to Shutter Tetris Pharma Unit; Ends License Deal with Xeris	Jan. 10	MT
Arecor Therapeutics plc - Shareholder/Analyst Call	Jan. 10
European blue-chips decline in tepid early trade	Dec. 30	AN
Arecor Therapeutics signs new drug licensing agreement	Dec. 30	AN
Arecor Therapeutics plc Signs Exclusive Licensing Agreement for Ready-To-Dilute Formulation of Speciality Hospital Product At351	Dec. 30	CI
Arecor Therapeutics names David Ellam as interim CFO	Nov. 18	AN
Arecor Therapeutics Names Interim CFO	Nov. 18	MT
Arecor Therapeutics plc Appoints David Ellam as Interim Chief Financial Officer	Nov. 18	CI
Arecor Therapeutics plc, H1 2024 Earnings Call, Oct 03, 2024	24-10-03
EARNINGS: Hansard Global profit down; Flowtech cuts outlook	24-09-26	AN
Arecor Therapeutics plc, H1 2024 Earnings Call, Sep 26, 2024	24-09-26
Earnings Flash (AREC.L) ARECOR THERAPEUTICS Posts H1 Revenue GBP2M	24-09-26	MT
Earnings Flash (AREC.L) ARECOR THERAPEUTICS Posts H1 Loss GBP-0.15	24-09-26	MT
Arecor Therapeutics plc Reports Earnings Results for the Half Year Ended June 30, 2024	24-09-26	CI
Arecor Therapeutics plc Presents Positive Data from Phase I Clinical Trial of Ultra-Concentrated, Ultra-Rapid Acting Insulins	24-09-11	CI
Arecor Therapeutics Completes Retail Offer	24-07-23	MT
Arecor Therapeutics Raises GBP7 Million via Share Placing, Subscription, retail offer	24-07-22	MT
Ingenta and Shearwater win deals	24-07-19	AN
Arecor Therapeutics plc Auditor Raises 'Going Concern' Doubt	24-06-10	CI
Political turmoil hits euro and banks	24-06-10	AN
Europe heads lower amid political turmoil in EU	24-06-10	AN
AIM WINNERS & LOSERS: Arecor Therapeutics dives on funding needs	24-06-10	AN
Arecor Therapeutics shares dive as says needs funding in third quarter	24-06-10	AN
Europe sinks, euro down amid French snap election	24-06-10	AN

Arecor Therapeutics plc is a United Kingdom-based globally focused biopharmaceutical company. The Company, by applying its technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver therapeutic products. Its portfolio includes AT247 - Ultra-Rapid Acting Insulin and AT278 - Ultra-Concentrated Ultra-Rapid Acting Insulin. Its lead product, AT247, is an Arestat enabled formulation of insulin designed to accelerate insulin absorption post injection, to enable effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes. The Company's AT278 is an ultra-concentrated novel formulation of ultra-rapid acting insulin. Its subsidiary, Tetris Pharma Ltd, has a portfolio of injectable products including Ogluo, which is a ready-to-use glucagon for emergency use to treat hypoglycemia.

Employees

Sector

Biotechnology & Medical Research

Calendar

2025-04-27 - Q4 2024 Earnings Release (Projected)

More about the company